Arcutis Biotherapeutics, Inc. ARQT
We take great care to ensure that the data presented and summarized in this overview for Arcutis Biotherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARQT
View all-
Jennison Associates LLC12.3MShares$306 Million0.14% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$269 Million3.33% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.5MShares$262 Million5.93% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$247 Million7.87% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$216 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$179 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X05.3MShares$132 Million0.54% of portfolio
-
State Street Corp Boston, MA4.64MShares$116 Million0.0% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY4.43MShares$111 Million0.99% of portfolio
-
Morgan Stanley New York, NY4.28MShares$107 Million0.01% of portfolio
Latest Institutional Activity in ARQT
Top Purchases
Top Sells
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Insider Transactions at ARQT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 05
2026
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
2,490
-2.58%
|
$69,720
$28.98 P/Share
|
|
Jan 02
2026
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-12.54%
|
$280,000
$28.96 P/Share
|
|
Dec 31
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
1,697
-0.87%
|
$49,213
$29.1 P/Share
|
|
Dec 15
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
11,500
-10.47%
|
$322,000
$28.94 P/Share
|
|
Dec 15
2025
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,500
+9.48%
|
$34,500
$3.64 P/Share
|
|
Dec 04
2025
|
Amit Munshi Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,021
+33.45%
|
-
|
|
Dec 01
2025
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-11.14%
|
$300,000
$30.21 P/Share
|
|
Dec 01
2025
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
1,657
-1.09%
|
$49,710
$30.23 P/Share
|
|
Nov 24
2025
|
Sue Jean Lin Director |
SELL
Open market or private sale
|
Direct |
25,272
-48.59%
|
$758,160
$30.78 P/Share
|
|
Nov 24
2025
|
Sue Jean Lin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,272
+20.46%
|
$202,176
$8.07 P/Share
|
|
Nov 24
2025
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
48,945
-6.2%
|
$1,468,350
$30.36 P/Share
|
|
Nov 21
2025
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
1,055
-0.13%
|
$31,650
$30.0 P/Share
|
|
Nov 20
2025
|
Halley E Gilbert Director |
SELL
Open market or private sale
|
Direct |
16,532
-42.77%
|
$446,364
$27.55 P/Share
|
|
Nov 20
2025
|
Halley E Gilbert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,220
+24.02%
|
$85,540
$7.51 P/Share
|
|
Nov 19
2025
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
2,550
-0.83%
|
$71,400
$28.23 P/Share
|
|
Nov 13
2025
|
Neha Krishnamohan Director |
SELL
Open market or private sale
|
Direct |
40,504
-33.99%
|
$931,592
$23.28 P/Share
|
|
Nov 13
2025
|
Neha Krishnamohan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
39,272
+25.63%
|
$314,176
$8.07 P/Share
|
|
Nov 13
2025
|
Keith R Leonard Director |
SELL
Bona fide gift
|
Direct |
4,312
-16.31%
|
-
|
|
Nov 06
2025
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
17,250
-14.93%
|
$414,000
$24.18 P/Share
|
|
Nov 06
2025
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,250
+12.99%
|
$51,750
$3.64 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 412K shares |
|---|---|
| Exercise of conversion of derivative security | 181K shares |
| Open market or private purchase | 27.4K shares |
| Bona fide gift | 1.99K shares |
| Open market or private sale | 718K shares |
|---|---|
| Bona fide gift | 6.31K shares |